Carvedilol is a racemic carbazole derivative (C24H26N2O4, MW 406.48) marketed as Coreg® and Dilatrend®. First- and second-generation beta blockers act only at beta adrenoceptors; carvedilol is classified as third-generation because it adds two further pharmacological dimensions: α₁-adrenergic blockade producing peripheral vasodilation, and intrinsic antioxidant activity that scavenges reactive oxygen species independently of receptor occupancy. Only the (S)-enantiomer carries the beta-blocking activity, while both enantiomers block α₁ receptors.

Metoprolol is β₁-cardioselective with no vasodilator or antioxidant component. Carvedilol is non-selective (blocks β₁ and β₂) and additionally blocks α₁ receptors, lowering systemic vascular resistance. Carvedilol is also metabolically neutral with respect to insulin sensitivity and lipids, whereas metoprolol can worsen both. The COMET trial (Poole-Wilson et al., Lancet 2003) compared the two head-to-head in 3,029 patients with chronic heart failure and reported lower all-cause mortality with carvedilol. For in vitro work, choose metoprolol when β₁ selectivity is required and carvedilol when broad adrenergic blockade or redox activity is the objective.

Reported K_i values are 0.81 nM at β₁, 0.96 nM at β₂ and 2.2 nM at α₁ adrenoceptors. In functional terms this gives roughly a 10- to 100-fold preference for beta over alpha₁ blockade. Carvedilol has no intrinsic sympathomimetic activity (ISA) and behaves as an inverse agonist at constitutively active beta receptors. At higher micromolar concentrations it also blocks cardiac K_IR channels and L-type Ca²⁺ channels.

Yes, and it is structurally attributable to the carbazole moiety. Yue et al. (J Pharmacol Exp Ther 1992) first showed that carvedilol inhibits iron-initiated lipid peroxidation in brain homogenates and protects cardiomyocytes from oxidative injury at concentrations independent of receptor blockade. Its major hydroxylated metabolite SB 211475 (4'-hydroxyphenyl carvedilol) is approximately 10-fold more potent as a radical scavenger. This dual pharmacology is the reason carvedilol frequently outperforms metoprolol and atenolol in oxidative-stress-driven models such as doxorubicin cardiotoxicity and ischemia-reperfusion injury.

Heart failure with reduced ejection fraction is driven by chronic sympathetic overactivation, which downregulates cardiac β₁ receptors and promotes fibrosis, apoptosis and adverse remodeling. Carvedilol interrupts this loop while unloading the ventricle via α₁ blockade. The COPERNICUS trial (NEJM 2001) demonstrated a 35% mortality reduction in severe HFrEF and the US Carvedilol Heart Failure Program (NEJM 1996) a 65% reduction in mortality risk — among the largest effect sizes reported for any heart failure therapy. Consequently it is the default positive control in TAC, coronary ligation and pacing-induced cardiomyopathy models.

Carvedilol is freely soluble in DMSO (>20 mg/mL) and soluble in ethanol and methanol, but is practically insoluble in water (~0.45 mg/L at 22.5°C, BCS Class II). For cell-based assays prepare a 10-50 mM DMSO stock, aliquot to avoid freeze-thaw cycles and store at -20°C protected from light; dilute into medium keeping the final DMSO concentration at or below 0.1% v/v. For oral gavage in rodents, common vehicles include 0.5% carboxymethylcellulose or DMSO/PEG300/Tween-80/saline. Because carvedilol is light sensitive, use amber vials throughout.

Biased agonism (functional selectivity) describes a ligand that differentially activates the two principal GPCR effector arms — G protein versus β-arrestin. Wisler et al. (PNAS 2007) showed that carvedilol acts as an inverse agonist for Gs-cAMP signalling yet a partial agonist for β-arrestin-dependent ERK1/2 activation at the β₂ adrenoceptor. This makes carvedilol one of the most cited reference biased ligands in GPCR pharmacology and a standard tool in BRET, TANGO and label-free biosensor assays exploring arrestin-mediated cardioprotection.

Yes. Classical non-selective beta blockade impairs β₂-mediated glycogenolysis and insulin secretion, worsening insulin resistance and triglyceride profiles. Carvedilol's concurrent α₁ blockade improves skeletal muscle perfusion and insulin sensitivity, offsetting these effects. In comparative studies it is described as metabolically neutral, which is why it is often selected as the beta blocker arm in diabetic cardiomyopathy, metabolic syndrome and chronic kidney disease models where metabolic confounding must be minimised.

Yes. Every batch of research-grade carvedilol ships with a Certificate of Analysis (COA) documenting HPLC purity (≥98%), ¹H/¹³C NMR structural confirmation, mass spectrometry, loss on drying and appearance. MSDS/SDS, residual solvent data, Certificates of Origin and stability statements are available on request. Sample evaluation is available to qualified academic and industrial laboratories — please contact us to discuss requirements.

Standard research packs of 1 g, 5 g, 10 g and 100 g are held in stock for immediate dispatch, and 1 KG industrial quantities are produced made-to-order for process development, formulation scale-up and CMO supply. Multi-kilogram campaigns, custom particle size distributions and specific impurity profiles can be accommodated. Bulk orders qualify for tiered pricing — request a quotation with your target quantity and specification.